Navigation Links
Amylin Pharmaceuticals to Present New Data from Broad Diabetes and,Obesity Programs at ADA 2007

SAN DIEGO, June 19, 2007 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that data featuring its approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, and its pipeline candidates will be presented at the American Diabetes Association's (ADA) 67th Annual Scientific Sessions being held in Chicago, IL from June 22 to 26. The company will also host an investor presentation during the meeting that will be available by webcast. ADA is one of the largest scientific meetings for endocrinologists and other health care professionals involved in diabetes research and delivery of diabetes care.

Data from several studies will be highlighted in oral presentations and poster sessions that will provide insight into Amylin's approved diabetes drugs, BYETTA and SYMLIN and the company's research and development programs. Additional information will also be presented during two symposia focused on the multihormonal approach to treatment of diabetes and obesity, and the role of incretin-based therapies in type 2 diabetes.

"Our activities at this year's ADA will reinforce the important therapeutic benefits of BYETTA and SYMLIN and focus on novel peptide hormones and their potential to treat obesity," said Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, Inc. "We are dedicated to bringing innovative medicines with life-changing therapeutic potential to patients. Our broad clinical program is designed to continue transforming the care of diabetes and obesity."

    KEY AMYLIN ABSTRACTS BEING PRESENTED AT ADA:


    1. Oral: "Less Hypoglycemia with Exenatide Versus Insulin Glargine,

       Despite Similar HbA1c Improvement in Patients with T2DM Adjunctively

       Treated with Metformin" will be presented by Michael E. Trautmann, M.D.

       on Sunday, June 24 at 3:45 PM CT (4:45 PM ET).


    2. Oral: 
"Exenatide Maintained Glycemic Control with Associated Weight

       Reduction Over Three Years in Patients with Type 2 Diabetes" will be

       presented by John B. Buse, M.D. on Monday, June 25 at 3:15 PM CT

       (4:15 PM ET).


    3. Poster: "Improvements in Cardiovascular Risk Factors Accompanied

       Improved Glycemic Control and Weight Reduction in Patients with Type 2

       Diabetes Treated with Exenatide for 3.5 y" will be presented by David

       Kendall, M.D. during a poster session on Sunday, June 24 at 12:00 PM CT

       (1:00 PM ET).


    4. Poster: "Pramlintide Improved Glycemic Control without Increased Risk

       of Hypoglycemia in Patients with Type 2 Diabetes Using Basal Insulin"

       will be presented by Karen Lutz, Ph.D.  during a poster session on

       Sunday, June 24 at 12:00 PM CT (1:00 PM ET).


    5. Oral: "Responsiveness to Leptin Restored by Amylin in Diet Induced

       Obese (DIO) Rats: Magnitude and Mechanisms of Synergy" will be

       presented by Jonathan Roth, Ph.D. on Monday, June 25 at 3:45 PM CT

       (4:45 PM ET).


    6. Oral: "Sustained Weight Loss Following 1-y Pramlintide Treatment as an

       Adjunct to Lifestyle Intervention in Obesity" will be presented by

       Steven Smith, M.D. on Monday, June 25 at 5:30 PM CT (6:30 PM ET).

A full list of all Amylin abstracts being presented at ADA is available at: http://scientificsessions.diabetes.org.

    FEATURED SYMPOSIA


    1. "The Diabetes-Obesity Continuum: The Growing Body of Evidence for a

       Multihormonal Approach to Treatment."  This medical education symposium

       will help healthcare providers understand the potential of

       multihormonal treatment approaches for diabetes and obesity.  The event

       will be chaired by Carol Hatch Wysham, M.D. on Sunday, June 24 at 5:30

       AM CT (6:30 AM ET).  This symposium is supported by an
 unrestricted

       educational grant from Amylin Pharmaceuticals.


    2. "The Role of Incretin-Based Therapies: Reconstructing Treatment

       Approaches in Type 2 Diabetes."  This medical education symposium will

       help healthcare providers understand the role of incretin-based

       therapies in relation to type 2 diabetes.  The event will be chaired by

       Bernard Zinman, M.D. on Monday, June 25 at 5:30 AM CT (6:30 AM ET).

       This symposium is supported by an unrestricted educational grant from

       Amylin Pharmaceuticals and Eli Lilly and Co.

Amylin will also conduct a webcast for investors to review the information presented at ADA on Sunday, June 24 at 7:30 PM CT (8:30 PM ET). The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately 15 minutes prior to the presentation to register and download any necessary audio software.


    More information about ADA can be found at

http://scientificsessions.diabetes.org.


About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,700 employees nationwide. For more information about Amylin visit http://www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Amylin's actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA or SYMLIN, and the revenues Amylin generates from these products, may be affected by competition, unexpected new data, technical issues, or manufacturing and supply issues; risks that the results of pre-clinical studies or clinical trials may not be predictive of future results; risks that our clinical trials will not start or be completed when planned; risks that the FDA may not approve Amylin's regulatory submissions; and risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA or SYMLIN. These and additional risks and uncertainties are described more fully

in Amylin's recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.

CONTACT: Alice Bahner Izzo of Amylin Pharmaceuticals, Inc.,+1-858-642-7272, cell, +1-858-232-9072, ; or RachelMartin of Edelman, +1-323-202-1031, cell, +1-323-373-5556,, for Amylin Pharmaceuticals, Inc. alice.izzo@amylin.com rachel.martin@edelman.com

Web site: http://www.amylin.com/http://scientificsessions.diabetes.org/

Ticker Symbol: (NASDAQ-NMS:AMLN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):